

Reference

- Annamaneni, S. et al., 2014. Methylation status of CEBPA gene promoter in chronic myeloid leukemia. *Hematology*, 19(1). Available at: <http://dx.doi.org/10.1179/1607845413Y.0000000081>.
- Apperley, J.F., 2015. Chronic myeloid leukaemia. *The Lancet*, 385(9976), pp.1447–1459. Available at: [http://dx.doi.org/10.1016/S0140-6736\(13\)62120-0](http://dx.doi.org/10.1016/S0140-6736(13)62120-0).
- Au, W.Y. et al., 2009. Chronic myeloid leukemia in Asia. *International Journal of Hematology*, 89(1), pp.14–23.
- Beer, P.A. et al., 2015. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. *Blood*, 125(3), pp.504–515.
- Burke, B. a, 2010. Effects of the Bcr-Abl Oncogene on Dna Damage and Repair. *Molecular Biology*.
- Castilla, L.H., 2008. C/EBP?? in Leukemogenesis: A Matter of Being in the Right Place with the Right Signals. *Cancer Cell*, 13(4), pp.289–291.
- Chang, J.S. et al., 2007. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2-dependent suppression of C/EBP?-driven myeloid differentiation. *Blood*, 110(3), pp.994–1003.
- Cuenca, G.M. & Ren, R., 2001. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. *Oncogene*, 20(57), pp.8236–8248. Available at: <http://www.nature.com/doi/10.1038/sj.onc.1205095> [Accessed January 2, 2017].
- Diger Hehlmann, R., 2012. How I treat CML blast crisis How I treat How I treat CML blast crisis. , 120(4), pp.737–748. Available at: <http://bloodjournal.hematologylibrary.org/content/120/4/737.full.html>.
- Ferrari-Amorotti, G. et al., 2006. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. *Blood*, 108(4), pp.1353–62. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16670262> [Accessed January 8, 2017].
- Frazer, R., Irvine, A.E. & McMullin, M.F., 2007. Chronic Myeloid Leukaemia in The 21st Century. *The Ulster medical journal*, 76(1), pp.8–17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17288299> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1940291>.
- Garcia-Manero, G. et al., 2003. Chronic myelogenous leukemia: A review and update of therapeutic strategies. *Cancer*, 98(3), pp.437–457.

- Jabbour, E.J. & Kanterjian, H., 2014. CME Information : Chronic myeloid leukemia : 2014 update. *American Journal of Hematology*, 89(5), pp.547–556.
- Lodish, H. et al., 2000. Post-Translational Modifications and Quality Control in the Rough ER.
- Longo, D. & Scadden, D., 2010. *the Cellular Basis of Hematopoiesis*,
- Nakahara, F. et al., 2012. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. , 115(14), pp.2872–2881.
- Pabst, T. et al., 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-[alpha] (C/EBP[alpha]), in acute myeloid leukemia. *Nature Genetics*, 27(3), pp.263–270. Available at: <http://www.nature.com/doi/10.1038/85820> [Accessed November 29, 2016].
- Perrotti, D. et al., 2010. Chronic myeloid leukemia: Mechanisms of blastic transformation. *Journal of Clinical Investigation*, 120(7), pp.2254–2264.
- Schuster, C. et al., 2003. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. *Blood*, 101(2), pp.655–663.
- Vardiman, J.W., Harris, N.L. & Brunning, R.D., 2002. Review article The World Health Organization (WHO) classification of the myeloid neoplasms. *October*, 100(7), pp.2292–2302.
- Waight, J.D. et al., 2014. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. *The Journal of biological chemistry*, 289(22), pp.15642–52. Available at: <http://www.jbc.org/content/289/22/15642.abstract> [Accessed October 25, 2016].
- Watanabe, T. et al., 2013. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia. *Cancer research*, 73(22), pp.6642–53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24242069>.